Northwest Bancshares Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,009 shares of the biopharmaceutical company’s stock after selling 590 shares during the quarter. Northwest Bancshares Inc.’s holdings in Pfizer were worth $1,581,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in PFE. Nuveen Asset Management LLC grew its stake in shares of Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after buying an additional 34,544,423 shares during the last quarter. Natixis bought a new position in shares of Pfizer during the second quarter valued at about $258,466,000. Invesco Ltd. grew its stake in shares of Pfizer by 14.6% during the second quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after buying an additional 2,693,349 shares during the last quarter. Thoroughbred Financial Services LLC grew its stake in shares of Pfizer by 4,297.8% during the second quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after buying an additional 2,596,269 shares during the last quarter. Finally, Marshall Wace North America L.P. grew its stake in shares of Pfizer by 52.9% during the first quarter. Marshall Wace North America L.P. now owns 7,431,974 shares of the biopharmaceutical company’s stock valued at $315,635,000 after buying an additional 2,571,626 shares during the last quarter. 71.69% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE PFE traded up $0.29 during trading hours on Wednesday, hitting $35.72. The company’s stock had a trading volume of 6,610,827 shares, compared to its average volume of 24,067,033. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The stock has a market cap of $198.73 billion, a price-to-earnings ratio of 11.91, a P/E/G ratio of 2.86 and a beta of 0.66. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The business has a 50-day simple moving average of $35.91 and a 200-day simple moving average of $40.03.

Pfizer (NYSE:PFE) last posted its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. Pfizer’s quarterly revenue was down 1.5% on a year-over-year basis. During the same period last year, the firm earned $0.77 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.81 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 4.03%. Pfizer’s payout ratio is 48.00%.

PFE has been the topic of a number of recent research reports. UBS Group reaffirmed a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. JPMorgan Chase & Co. raised their price objective on Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, September 19th. They noted that the move was a valuation call. Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Morgan Stanley cut their target price on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 27th. Thirteen equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $45.25.

In other news, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now owns 3,000 shares in the company, valued at approximately $104,160. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Institutional Investors

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.